Servier unveils its 2030 ambition and reveals a new visual identity


  • A new ambition by 2030 to speed up its transformation dynamic
  • A visual identity, a marker of the profitable transformation of the Group, its ambitions and its renewal 

PARIS, Oct. 6, 2022 /PRNewswire/ — Servier at this time unveils its 2030 ambition in addition to a new visual identity that displays the transformation undertaken by the Group, bringing seen outcomes. The Group intends to speed up its transformation dynamics with a view to guarantee, over the long run, its independence and its creation of worth for all its stakeholders. Servier confirms its dedication to creating a significant social affect and contributing to a sustainable world. 


A metamorphosis that results in outcomes

Servier dedicated in 2015 to a transformation geared toward sustainably bettering the corporate’s efficiency and guaranteeing the sustainability of its distinctive governance mannequin for the final word good thing about sufferers. Being ruled by a basis additionally offers the Group a long-term imaginative and prescient, completely tailored to the lengthy cycles of the pharmaceutical sector. 

In latest years, Servier has strengthened its management in cardiovascular ailments, the main reason behind mortality worldwide[1] – Servier is the threerd largest international pharmaceutical group in cardiology and in hypertension.[2] Drawing on acknowledged scientific know-how, the Group has developed a wide selection of therapies distributed in 150 international locations. Servier has considerably invested in incremental innovation, together with Single Pill Combinations (SPCs), a number of medicines mixed into a single pill, which ends up in higher affected person compliance and contributes to financial savings for the healthcare system. Servier can be a famend international chief in venous ailments, because of daflon® which is a crucial a part of the Group’s development.

Servier has made a main shift in oncology as a new pillar of strategic development. The Group allocates over 50% of its R&D funds to it, with the ambition to turn out to be a famend and modern participant within the growth of therapeutic options focusing on hard-to-treat cancers. Servier leads its R&D applications round two approaches: immuno-oncology and focused therapies. Over the previous 4 years, the Group has considerably strengthened its place in oncology because of greater than €6 billion investments, together with two main acquisitions which have made it potential to ascertain a presence in new strategic territories corresponding to the United States and Japan. The Group’s main funding in oncology at this time ends in a wealthy pipeline of 39 R&D initiatives and seven medicines accessible to sufferers.  

The Group additionally consolidated its generic business by way of nationwide champions with sturdy manufacturers corresponding to Biogaran in France, Egis in Eastern Europe, Pharlab in Brazil and Swipha in Nigeria. This exercise opens entry to high quality look after the biggest variety of folks and contributes to reducing healthcare prices.

The transformation has impacted all of the Group’s actions, together with R&D, which has undertaken a transformation plan based mostly on three pillars that help progress and therapeutic efficiency: a patient-centric strategy, a extra environment friendly group with a collaborative dynamic, and a refocusing on 4 therapeutic areas (oncology, cardiometabolism, neuroscience and immuno-inflammation). In its ambition to construct a very open, dynamic and productive analysis for the good thing about sufferers, the opening of the Servier Research and Development Institute at Paris-Saclay in 2023 is a main step within the transformation of R&D. The results of an funding of greater than €370 million, it’s located on the middle of a international scientific and technological innovation cluster. The future Institute would be the coronary heart of the Group’s international R&D group and will work cross-functionally with Servier’s different R&D facilities based mostly in Denmark (Ballerup), the United States (Boston) and Hungary (Budapest). It will accommodate 1,500 staff and will embody an incubator housing roughly 15 start-ups.

See also  ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV

The Group has additionally accelerated its digital transformation to create worth for sufferers and healthcare stakeholders, whereas unlocking the potential of groups, by way of new agile and environment friendly methods of working in addition to a remodeled infrastructure.

Relying on a stable basis, the Group is now in a position to verify its trajectory to 2025 – a income of

€6 billion, together with €1 billion in oncology, and a Group EBITDA of €1.3 billion – and to ambitiously tackle the second strategic step of its transformation plan by 2030.  

Olivier Laureau, President of Servier, says: “I want to thank all the employees of the Group who contribute to the success of the company’s profound transformation, recognized worldwide by healthcare professionals, patient associations and our partners. The path we have travelled has allowed us to value our uniqueness: Servier is a group governed by a foundation whose ultimate beneficiary is and will always be the patient. This independence allows us to invest in the long-term for the development of innovative therapeutic solutions to meet high unmet medical needs.”

A 2030 imaginative and prescient and ambition to speed up the Group’s transformation 

Building on the 2025 objectives as an necessary milestone, Servier has set a 2030 ambition to speed up its transformation. The Group thus intends to attain a turnover of €8 billion in 2030 with an EBITDA of greater than 30% by way of a technique based mostly on three pillars:

1 – Be a mid-size, targeted and modern participant in oncology in addition to in neuroscience and immuno-inflammation

Thanks to the key investments made in R&D, the Group has sturdy innovation capabilities and a wealthy pipeline of initiatives focusing on pathologies with a excessive unmet medical want. Servier thus intends to launch a new molecular entity, or a new indication, yearly in oncology and to attain a main launch within the space of neuroscience/immuno-inflammation by 2030. Servier units a purpose of attaining an oncology income larger than or equal to €3 billion in 2030.

2 – Accelerate the Group’s management in cardiometabolism and venous illness 

See also  New to The Street Signs Apotheosis Investments Global, Inc.

Servier may be very concerned within the growth of incremental improvements (Single Pill Combinations) in addition to modern digital companies that goal to enhance analysis, information of power ailments and therapeutic compliance. The Group develops partnerships with affected person associations to supply companies which might be greatest suited to the wants of sufferers and their households. The Group intends to attain a income larger than or equal to €3 billion in 2030 on this space by counting on a famend experience, a sturdy capability for incremental innovation and an intensive worldwide presence.

3 – Continue the worthwhile development of the Generic business  

Relying on nationwide champions, the Group needs, by way of its Generic business, to facilitate entry to therapies for a largest variety of sufferers. This business will seize the market alternatives provided by patent exclusivity losses and biosimilar growth, with a focused income of €1.8 billion by 2030.

Three strategic levers will assist obtain the Group ambition:

1 – An optimized industrial community 

To help its development and its growth, Servier will depend on an industrial mannequin based mostly on an environment friendly and sustainable community of specialised manufacturing websites, suited to the evolution of its medicines’ portfolio. This mannequin will even use digital applied sciences (Artificial Intelligence and Big information) with a view to present visibility into the commercial exercise and to anticipate manufacturing administration from starting to finish (end-to-end provide chain).

2 – Agile and environment friendly group  

An agile and environment friendly group, aligned with strategic ambitions, is a key efficiency lever. That is why Servier will strengthen cross-functional decision-making and collaboration with a view to permit everybody inside the Group to avoid wasting time and give attention to duties with excessive added worth. In addition, digital applied sciences will profit all actions of the Group, and will assist improve its effectiveness, efficiency and therapeutic innovation functionality.

3 – A group of staff dedicated to future generations  

Since its creation, Servier has positioned staff on the middle of its actions, recognizing them because the Group’s important power. To make Servier 2030 a success, for the good thing about sufferers, the Group creates an atmosphere encouraging expertise engagement, retention and attraction.

Beyond the sturdy commitments already made to scale back its carbon footprint, speed up variety and inclusion and help communities, specifically by way of Mécénat Servier, the Group plans to spend money on a flagship CSR challenge each three years.

A new visual identity emblematic of the Group’s transformation

The transformation undertaken, of which the outcomes are seen to the entire Group’s stakeholders, led Servier to alter its visual identity by adopting a model platform that displays the Group’s renewal.

This new identity displays what animates and represents Servier’s uniqueness: an impartial group, ruled by a basis, dedicated to therapeutic progress to serve affected person wants. It is the marker of Servier’s profitable transformation, its ambitions and its renewal. It additionally displays the distinctiveness of the Group that works for the frequent good and absolutely integrates CSR into its technique.

See also  JumpCloud Wins 2022 CrowdStrike Ecosystem Emerging Partner

The “moved by you” signature and the star symbolize the Group’s proximity to its stakeholders (sufferers, companions and staff). The smile, represented by the curve of the “R”, offers hope for sufferers. It symbolizes the eagerness, empathy, experience and innovation that characterize Servier.

This new model platform unites all staff round a frequent identity, a supply of inspiration on a each day foundation. It additionally strengthens the Group’s employer model: its vocation, and its independence assured by its basis standing, reply to the youthful generations’ seek for which means.

Olivier Laureau, President of Servier, provides: “Our Group is founded on a vocation that inspires us and around strong values that drive us. The initiated transformation and our ambition represent a new chapter in our history. More than ever, with Servier 2030, we are focused on innovation and positive social impact thanks to an improved profitability and bold choices.”

Press contact:

About Servier

Founded to serve well being, Servier is a international group ruled by a Foundation that aspires to have a significant social affect, each for sufferers and for a sustainable world. With its distinctive governance mannequin, it could absolutely serve its vocation with a long-term imaginative and prescient: being dedicated to therapeutic progress to serve affected person wants. The 21,800 staff of the Group are dedicated to this shared vocation, supply of inspiration day-after-day.

As a world chief in cardiology, Servier’s ambition is to turn out to be a famend, targeted and modern participant in oncology by focusing on hard-to-treat cancers. That is why the Group allocates over 50% of its R&D funds to growing focused and modern therapies in oncology.

Neuroscience and immuno-inflammatory ailments are the longer term development driver. In these areas, Servier is targeted on a restricted variety of ailments through which correct affected person profiling makes it potential to supply a focused therapeutic response by way of precision drugs.

To promote entry to high quality look after all at a decrease value, the Group additionally gives a vary of high quality generic medication masking most pathologies, counting on sturdy manufacturers in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group contains the affected person voice at every stage of the life cycle of a drugs.

Headquartered in France, Servier depends on a sturdy geographical footprint in over 150 international locations and achieved a income of €4.7 billion in 2021.

More info on the new Group web site:

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram

Logo –


[1] Inserm, 2017 

[2] Source IQVIA, Analytics Link / World 74 international locations / Mat Q1 2022

Servier unveils its 2030 ambition and reveals a new visual identity

Cision View unique content material to obtain multimedia:

Source link


Please enter your comment!
Please enter your name here